TB is a leading cause of death in South Africa, yet often goes undiagnosed. Community-based GeneXpert MTB/RIF screening may expedite TB diagnosis and treatment.
We conducted a proof-of-concept randomized trial to evaluate the yield of GeneXpert screening on a mobile HIV testing unit at community venues in Umlazi Township, Durban. Eligible adults (≥18y) underwent rapid HIV testing and a TB symptom screen and were randomized to usual care or intervention. Participants with TB symptoms in the usual care arm were asked to produce a sputum sample, for GeneXpert testing at the provincial hospital laboratory; participants were contacted ~7 days later with results and treatment referral. In the ‘Test & Treat TB’ intervention, all HIV-infected or HIV-uninfected/TB symptomatic participants able to produce sputum underwent GeneXpert testing on the mobile unit. GeneXpert-positive participants received expedited TB treatment initiation on the mobile unit as well as monthly SMS reminders and non-cash incentives for picking up test results, linking to an initial clinic visit, and TB treatment completion. We assessed linkage to TB care and 6-month TB treatment outcomes.
We screened 7,361 people over 20 months. 4,815 were eligible and enrolled; median age was 27 (IQR 22 to 35), 51% were male, and 95% reported prior HIV testing. TB symptoms included cough (5%), weight loss (4%), night sweats (4%), and fever (3%). Overall, 42% of eligible participants could produce sputum samples (intervention: 55%; usual care: 26%). Among intervention participants, 41% exhibiting no TB symptoms successfully produced sputum compared to those with 1 (48%), 2 (71%), 3 (72%), or 4 (89%) symptoms. Seven participants tested GeneXpert-positive, six in the intervention arm (3%, 95% CI 1%, 5%) and one in the usual care arm (1%, 95% CI 0%, 6%). All 6 in the intervention arm linked to care within 6 months, and 5 of the 6 completed treatment; the GeneXpert-positive participant in the control arm did not link to care and did not complete TB treatment.
Screening for TB on a mobile HIV testing unit in the community using GeneXpert is feasible, though likelihood of specimen production is higher among those with more TB symptoms. Overall yield for GeneXpert-positive TB was low, however, the expedited ‘Test & Treat TB’ strategy led to rates of TB treatment completion comparable to clinic-initiated treatment in South Africa.